These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19581647)

  • 21. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
    Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
    Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
    MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
    [No Abstract]   [Full Text] [Related]  

  • 27. Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
    Ogawa S; Mori T; Nako K; Ishizuka T; Ito S
    Clin J Am Soc Nephrol; 2008 Mar; 3(2):362-8. PubMed ID: 18235151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A; Bashir K; Anwar E
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
    Agha A; Amer W; Anwar E; Bashir K
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
    Basi S; Lewis JB
    Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
    Dalla Vestra M; Simioni N; Masiero A
    Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
    Chen Y; Liu P; Chen X; Li Y; Zhang F; Wang Y
    Am J Med Sci; 2018 May; 355(5):418-424. PubMed ID: 29753370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
    Ingelfinger JR
    N Engl J Med; 2011 Mar; 364(10):970-1. PubMed ID: 21388316
    [No Abstract]   [Full Text] [Related]  

  • 35. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
    Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
    Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Primary prevention of diabetic nephropathy].
    Trevisan R
    G Ital Nefrol; 2012; 29 Suppl 58():S49-53. PubMed ID: 23229603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-receptor blockade in renal disease: the hard issues.
    Sica DA
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):469-71. PubMed ID: 15225107
    [No Abstract]   [Full Text] [Related]  

  • 39. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
    Consuegra-Sánchez L; Sanchis J; Núñez J; Cascón JD; Villegas M; Picó F
    Rev Esp Cardiol (Engl Ed); 2012 Apr; 65(4):378-80. PubMed ID: 21840109
    [No Abstract]   [Full Text] [Related]  

  • 40. Telmisartan in incipient and overt diabetic renal disease.
    Schmieder RE; Bakris G; Weir MR
    J Nephrol; 2011; 24(3):263-73. PubMed ID: 21374585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.